3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Plasma cell
1
Other hematologic neoplasm
1
Lymphoid
1
Dermatologic
1
Conditions
Lymphoma, T-Cell, Peripheral
4
Lymphoma, T-Cell
4
Lymphoma, Large-Cell, Anaplastic
3
Recurrence
2
Multiple Myeloma
2
Lymphoma, Follicular
2
Immunoblastic Lymphadenopathy
2
Esophageal Squamous Cell Carcinoma
2
Adenocarcinoma Of Esophagus
2
Waldenstrom Macroglobulinemia
1
Unspecified Adult Solid Tumor, Protocol Specific
1
Subcutaneous panniculitis-like T-cell lymphoma
1
Stomach Neoplasms
1
Ovarian Neoplasms
1
Mycosis Fungoides
1
Lymphoma, T-Cell, Cutaneous
1
Lymphoma, Non-Hodgkin
1
Lymphoma, Mantle-Cell
1
Lymphoma, Large B-Cell, Diffuse
1
Lymphoma, B-Cell, Marginal Zone
1
Lymphoma
1
Lung Neoplasms
1
Leukemia, Lymphocytic, Chronic, B-Cell
1
Hodgkin Disease
1
Head and Neck Neoplasms
1
Fallopian Tube Neoplasms
1
Esophageal Neoplasms
1
Enteropathy-Associated T-Cell Lymphoma
1
Carcinoma, Non-Small-Cell Lung
1
Burkitt Lymphoma
1
Interventions
Cyclophosphamide
117
Rituximab
115
fludarabine phosphate
79
Peripheral Blood Stem Cell Transplantation
71
Mycophenolic Acid
55
Whole-Body Irradiation
52
Filgrastim
49
Tacrolimus
43
Cyclosporine
43
Radiotherapy
41
Busulfan
41
Antilymphocyte Serum
38
Etoposide
36
Melphalan
34
Lenalidomide
31
Methotrexate
25
fludarabine
23
Cord Blood Stem Cell Transplantation
22
Bortezomib
20
Flow Cytometry
19
Cytarabine
19
Methylprednisolone
18
Bendamustine Hydrochloride
18
obinutuzumab
17
Prednisone
15
Granulocyte Colony-Stimulating Factor
15
Carmustine
15
sargramostim
14
orelabrutinib
14
Therapeutics
13
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
OTHER
×
Lymphoma, B-Cell, Marginal Zone
×
10-propargyl-10-deazaaminopterin
×
Clear all
NCT01947140
2022-11-23
PDX+Romi
Columbia University
Phase 1/2
Completed
57 enrolled